COMMUNIQUÉS West-GlobeNewswire

Censozo Announces Online Educational Resources Focused on Wellness, Recovery Support, and Personal Growth
09/07/2026
Censozo expands access to educational content and self-help resources designed to support wellness awareness and personal development. Censozo online wellness and self-help resources. CHICAGO, July 09, 2026 (GLOBE [...]
The Lenny Peters Foundation and 20 Years of Transforming Lives and Communities
09/07/2026
High Point, NC, July 09, 2026 (GLOBE NEWSWIRE) -- The Lenny Peters Foundation is celebrating two decades of steadfast service, impactful giving and commitment to improving lives in North Carolina’s Piedmont Triad region [...]
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
09/07/2026
First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical Development Novel 13-point edited CAR T cell Built with [...]
Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event
09/07/2026
Live video webcast on Tuesday, July 14 th , at 4:00 PM ET Register here SAN DIEGO, July 09, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on [...]
TOMI Reports 124% Increase in Preliminary Second Quarter Revenue; Preliminary Six Months Revenue Combined with Open Orders Surpass Full Year 2025 Revenue
09/07/2026
FREDERICK, Md., July 09, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today reported robust preliminary second-quarter 2026 [...]
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
09/07/2026
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus ® (ocrelizumab), including both intravenous and subcutaneous formulations. Agreement advances Teva’s Pivot to [...]
Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome
09/07/2026
Quoin Expects to Initiate Phase 2 Study in 2H 2026, Study Plans to Enroll 6-8 Pediatric and Adult Patients in the U.S. and Europe FDA Expressed No Safety Concerns Over Study Design and Duration of Dosing First-Ever [...]
Cynet Releases 2026 Global AI Security Readiness Report
09/07/2026
New report shows more than half of in-house security teams want managed service providers (MSPs) involved when adopting new cybersecurity capabilities, while 60% reporting security incidents BOSTON, July 09, 2026 (GLOBE [...]
ENvue Medical Unveils Its First Robotic-Assisted, Artificial Intelligence, Feeding Tube Automation Tool
09/07/2026
ENvue Targeting Combined $10 Billion+ Enteral Feeding and Vascular Access Market Opportunity* ENvue Drive ™ Demonstration Marks First Step Toward a New Generation of Intelligent Bedside Procedures and Integrates ENvue’s [...]
Xealth Launches Support for Health Systems’ CMS ACCESS Participation, Targeting Up to 5% MSSP ACO Savings
09/07/2026
The company will also connect ACCESS participants with healthcare providers, facilitating referrals through its platform SEATTLE, July 09, 2026 (GLOBE NEWSWIRE) -- Xealth , the leader in digital health orchestration and [...]
Heald Expands Access to AI-Powered Glucose Intelligence for Over-the-Counter CGM Users
09/07/2026
Consumers purchasing Dexcom Stelo or Abbott Lingo through Heald now receive complimentary access to AI-powered glucose insights ALPHARETTA, Ga., July 09, 2026 (GLOBE NEWSWIRE) -- Heald, a digital metabolic health [...]
Atsena Therapeutics Selects ATSN-401 Clinical Candidate, a Potential Best-in-Class Gene Therapy for Stargardt Disease
09/07/2026
Proprietary dual-vector platform delivers full-length ABCA4, enabled by Atsena's laterally spreading AAV.SPR capsid for delivery to the central retina without foveal detachment ATSN-401 advancing in IND-enabling studies [...]
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
09/07/2026
Cohort 1 Topline Data Expected in the Second Week of September 2026 RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a [...]
Fangzhou Named to KPMG China Healthcare 50 for AI-Powered Chronic Disease Care
09/07/2026
SHANGHAI, July 09, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, has been named to the KPMG China Healthcare 50 list, [...]
Tris Pharma Launches Adneuris Therapeutics to Advance a New Era in Pain Medicine
09/07/2026
Tris Pharma’s Wholly-Owned Subsidiary is Advancing the Development of Cebranopadol as it Prepares for New Drug Application (NDA) Submission Later This Year MONMOUTH JUNCTION, N.J., July 09, 2026 (GLOBE NEWSWIRE) -- [...]
NetraMark Signs New Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner
09/07/2026
New agreement is a significant commercial milestone and the Company’s first with its contract research organization partner Agreement expands NetraMark’s portfolio of AI-driven projects in central nervous system (CNS) [...]
Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01
09/07/2026
STAFFORD, Texas, July 09, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
What Clinicians Ask About Cartilage Regeneration Supplements: Answering the Clinical Questions Around Cartigenix HP®
09/07/2026
Three published human studies covering more than 1,700 participants provide peer-reviewed answers to the clinical questions most frequently raised about cartilage regeneration supplementation*† SCOTTSDALE, AZ, July 09, [...]
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC
09/07/2026
Advanced MRI analyses showed early treatment-related changes in white matter myelin integrity and cortical microstructure at Week 24, supporting biologic activity of selective soluble TNF inhibition. White matter myelin [...]

Pages